Fast™
Etiology
Suspected NAFLD patients
Target
NASH + NAS≥4 + F≥2
Uses
Screening for clinical trial and identifying at-risk NASH patients
FibroScan® results (LSM by VCTE™ & CAP™) + laboratory parameter (AST)
Enhancing FibroScan® liver disease assessment with biological markers
A single biomarker cannot answer to all questions.
With FibroScan®-based scores, you can combine FibroScan® results with other parameters to get the best performance and a better identification of your patients.
Scores by echosens are available on myFibroScan application.
Suspected NAFLD patients
NASH + NAS≥4 + F≥2
Screening for clinical trial and identifying at-risk NASH patients
FibroScan® results (LSM by VCTE™ & CAP™) + laboratory parameter (AST)
Suspected NAFLD patients
F≥3
Identifying NAFLD patients with advanced fibrosis and predicting risk of complications
LSM by VCTE™ + Clinical parameters (AST, ALT, Platelets, Presence of Diabetes, Age and Gender)
Suspected NAFLD patients
F4
Identifying NAFLD patients with cirrhosis that need to be screen for HCC
LSM by VCTE™ + Clinical parameters (AST, ALT, Platelets, Presence of Diabetes and Gender)
The non-invasive solution for comprehensive management of liver health
Your everyday FibroScan® companion – free application
Optimize clinical workflows with real-time secure data transmission
Agile 3+, Agile 4, Fast™ are non-devices Clinical Decision Supports (CDS) that meet the criteria outlined in section 520(o)(1)(E) of the FD&C Act.
Fast™ calculator is a tool for clinicians, computed from LSM and CAP (obtained from FibroScan® device) and AST blood parameter measurement, to aid in the identification of a patient with suspicion of NAFLD as being at risk for active fibrotic NASH (NASH+NAS≥4+F≥2). Agile 3+ calculator is a tool for clinicians, computed from LSM (obtained from FibroScan® device), AST, ALT, platelets, diabetes status, age and gender, to aid in the identification of patients with suspicion of NAFLD as having advanced fibrosis. Agile 4 calculator is a tool for clinicians, computed from LSM (obtained from FibroScan® device), AST, ALT, platelets, diabetes status and gender, to aid in the identification of patients with suspicion of NAFLD as having cirhhosis.
These scores were developed based on pools of cohorts and are published in peer-reviewed literature. They are presented as educational services intended for licensed healthcare professionals. While these scores are about specific medical and health issues, they are not substitutes for or replacements of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.